Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009
... treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its ZFP Technology, including Dow ...Sangamo BioSciences Announces Presentation at the JMP Securities Research Conference
... treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By ...Sangamo BioSciences Reports First Quarter 2009 Financial Results
... treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By ...New stem cell technique improves genetic alteration
... could use the technique to correct the disorder in stem cells, then use the healthy cells in a treatment. The method potentially could help treat monogenic diseases, which result from modifications in a single gene occurring in all cells of the body. Though relatively rare, these diseases affect millions ...Genetic susceptibility in viral encephalitis
... a substantial risk. "In contrast to most current thinking, we suspected that herpes simplex encephalitis susceptibility could be inherited as a monogenic trait resulting in the specific impairment of immunity to herpes simplex virus-1," Beutler said. "Here we have defined a genetic lesion that is ...Researchers Create First Targeted Knockout Rats Using Zinc Finger Nuclease Technology
... treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). ...Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
... treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). ...Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives
... and ALS. Other therapeutic development programs are focused on cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By ...Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
... development programs are focused on stem cell mobilization, ALS, cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By ...A new analysis method allows to find out the sex of the baby from the second month of pregnancy
... send it to Lorgen and receive the results 48 hours later. Diagnosis of monogenic diseases This new process, apart from saving the parents the wait until ... with important medical applications; especially in the diagnosis of monogenic diseases related to X chromosome, such as haemophilia or Duchenne muscular ...Sangamo BioSciences to Present at the Bank of America 2008 Healthcare Conference
... development programs are focused on stem cell mobilization, ALS, cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By ...The importance of gene regulation for common human disease
... our analysis will help to develop that understanding, a vital step on the path from genetics to improvements in healthcare." Past studies of rare, monogenic disease, such as cystic fibrosis and sickle-cell anaemia, have focused on changes to the protein-coding regions of genes because they have been ...Sangamo BioSciences Reports Second Quarter 2009 Financial Results
... treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its ZFP technology, including Dow ...Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast
... treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its ZFP Technology, including Dow ...Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference
... treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By ...Sangamo BioSciences Announces First Quarter 2009 Conference Call and Webcast
... treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). ...Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results
... treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). ...Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
... and ALS. Other therapeutic development programs are focused on HIV/AIDS, cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). ...Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
... and ALS. Other therapeutic development programs are focused on cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). ...